Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2022-02-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 20 pages 2.4MB
Interim / Quarterly Report Classification · 100% confidence The document is an announcement from PYC Therapeutics regarding the submission of Appendix 4D and the Interim Financial Statements for the half-year ended 31 December 2021. It includes detailed financial data such as revenues, losses, net tangible assets, and a directors' report. The document also contains an auditor's independence declaration and a comprehensive review of operations and financial results for the half-year period. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and detailed content confirm it is the report itself, not merely an announcement of its publication. H1 2022
2022-02-27 English
PYC Increases Shareholding in Vision Pharma 2 pages 170.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 17 February 2022 about PYC Therapeutics increasing its shareholding in its subsidiary Vision Pharma through a $10 million recapitalization. It discusses the shareholding percentages before and after the transaction and the purpose of the recapitalization to fund clinical trials. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The content focuses on a capital structure change and investment activity. The document length is 4594 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best into the category of Capital/Financing Update (CAP).
2022-02-16 English
Becoming a substantial holder 3 pages 319.8KB
Regulatory Filings
2022-02-01 English
Quarterly Activities and Appendix 4C Cash Flow Report 8 pages 221.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'REPORT FOR THE QUARTER ENDED 31 DECEMBER 2021 (Q4)' and contains detailed financial data including cash flow statements for the quarter and year-to-date periods. It discusses operational progress, drug development pipeline updates, and includes an Appendix 4C which is a quarterly cash flow report required by the ASX Listing Rules. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2021
2022-01-26 English
Notification of cessation of securities - PYC 4 pages 24.4KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from PYC Therapeutics Limited regarding the cessation of certain securities, specifically options that have lapsed due to conditions not being met. It details the number of securities ceased, reasons for cessation, and the updated issued capital following these changes. The document is short (4362 characters) and focuses on changes in issued capital and securities status rather than financial performance or detailed financial data. It does not contain financial statements or management discussion but is a formal notification about securities changes. This fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes such as option lapses or cancellations.
2022-01-06 English
Change in substantial holding 2 pages 547.7KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder in PYC Therapeutics. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory filing specifically about shareholding changes.
2021-12-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.